What Shanghai Kaibao Pharmaceutical does

Shanghai Kaibao Pharmaceutical Co., Ltd. (上海凯宝药业股份有限公司) is a modern Chinese medicine company founded in 2000 and listed on the Shenzhen Stock Exchange ChiNext Board in 2010 under ticker 300039, making it one of the first ChiNext-listed companies in Shanghai's Fengxian District. The company focuses on the research, development, manufacturing, and sale of modern Chinese medicine formulations spanning three therapeutic domains: respiratory (anchored by its patented flagship Tanreqing Injection and Tanreqing Capsule), cardiovascular and cerebrovascular (Qishen Capsule), and digestive/hepatic (Tiopronin series). Manufacturing is anchored at a 600 million yuan modern factory occupying 120 mu in the Shanghai Industrial Comprehensive Development Zone, supplemented by a wholly-owned regional subsidiary in Xinxiang (Henan).

The company operates a traditional pharmaceutical go-to-market model, selling prescription products directly to hospitals and medical institutions across China through licensed pharmaceutical distributors and wholesalers, with pricing subject to national drug pricing regulations and tender processes. It also offers a 'Big Health' consumer product line through a wholly-owned health technology subsidiary and an equity investment management subsidiary for treasury and strategic investment activities. Revenue is generated primarily through one-time product sales rather than licensing or subscription models, and the company holds the exclusive patent on Tanreqing Injection and has secured inclusion of certain products in China's National Essential Drug List (2026 edition). Recent strategic activity includes initiation of a Phase II clinical trial for KBZ24020 in June 2026 and completion of an insider share increase plan by the controlling shareholder and senior management.

Name

Shanghai Kaibao Pharmaceutical

Legal name

上海凯宝药业股份有限公司

Website

https://xykb.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Shanghai Kaibao Pharmaceutical is a modern Chinese medicine company, listed on SZSE ChiNext (300039), that develops, manufactures, and sells patented prescription drugs in respiratory, cardiovascular, and digestive therapeutics to Chinese hospitals and medical institutions via distribution networks.

Ownership category

akta.pro rank

Product category

Modern Chinese Medicine (Pharmaceuticals)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Modern Chinese medicine
• Pharmaceutical manufacturing
• Respiratory therapeutics
• Cardiovascular medicine
• Hepatoprotective products

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling modern Chinese medicine products including injections, capsules, and other pharmaceutical preparations. Products are distributed to hospitals and medical institutions through pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Shanghai Kaibao Pharmaceutical is a modern Chinese medicine company engaged in the R&D, production, and sales of prescription pharmaceutical products across three therapeutic areas: respiratory (anchored by the flagship exclusive patented Tanreqing Injection and Tanreqing Capsule), cardiovascular/cerebrovascular (Qishen Capsule), and hepatobiliary/digestive (Tiopronin series), plus a Big Health Products line. Products are manufactured at the company's modern factory in Shanghai Industrial Comprehensive Development Zone and sold through pharmaceutical distribution channels to hospitals and medical institutions across China.

Product overview

Shanghai Kaibao Pharmaceutical is a modern Chinese medicine company engaged in R&D, production, and sales. The company operates a platform-plus-domains architecture with three main therapeutic areas: respiratory (represented by 痰热清注射液 and 痰热清胶囊), cardiovascular/cerebrovascular (represented by 芪参胶囊), and digestive/hepatic (represented by 硫普罗宁 series products). Additionally, the company offers big health products as part of its broader portfolio. The flagship product is 痰热清注射液, an exclusive patented injection.

Differentiator

Problem solved

Functional benefit

Brands

• 痰热清注射液 (Tanreqing Injection): Exclusive patented respiratory product, the company's leading product
• 痰热清胶囊 (Tanreqing Capsule)
• 芪参胶囊 (Qishen Capsule)
• 大健康产品 (Grand Health Products)

Products and services

• Tanreqing Injection (痰热清注射液)

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. (上海凯宝新谊（新乡）药业有限公司)coreOthersA wholly-owned subsidiary engaged in pharmaceutical manufacturing, extending the company's production capabilities across different regions of China.
• Shanghai Kaibao Equity Investment Management Co., Ltd. (上海凯宝股权投资管理有限公司)minorOthersA wholly-owned subsidiary focused on equity investment management activities, supporting the parent company's financial and investment strategies.
• Shanghai Kaibao Health Technology Co., Ltd. (上海凯宝健康科技有限公司)coreOthersA wholly-owned subsidiary focused on health technology, supporting the company's expansion into broader healthcare and wellness product categories including big health products.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Joincare Pharmaceutical Group: Chinese pharmaceutical company with respiratory, digestive, and cardiovascular product lines including injectable formulations. Comparable mid-cap multi-therapeutic platform with hospital-channel distribution.

Direct peers

• Zhendong Group: Modern Chinese medicine company with proprietary injectable and capsule formulations in respiratory and adjacent areas. Direct competitor in TCM injection commercialization through hospital channels in China.
• Livzon Pharmaceutical Group: Diversified Chinese pharmaceutical company with significant TCM and chemical drug operations across respiratory, cardiovascular, and digestive indications. Comparable scale, listing status, and multi-domain product strategy.
• Tongrentang (China Traditional Chinese Medicine): Iconic traditional Chinese medicine brand with both prescription and OTC offerings across multiple therapeutic categories. Comparable in TCM heritage, hospital sales channels, and platform-style therapeutic diversification.
• Yunnan Baiyao Group: Major branded Chinese medicine manufacturer with patented flagship products and a diversified therapeutic portfolio plus consumer health line. Comparable business model combining TCM R&D, manufacturing, and broad distribution in China.
• China Resources Sanjiu Medical & Pharmaceutical: Leading Chinese OTC and prescription TCM company with a similar modern Chinese medicine platform spanning multiple therapeutic areas. Highly comparable in product format (injections/capsules), regulatory profile, and hospital-and-pharmacy distribution model in China.
• Dong-E-E-Jiao: Branded TCM and health products company with a flagship proprietary product and expansion into consumer wellness. Comparable patented-product moat and China hospital-plus-retail distribution model.

Broad incumbents

• Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharma company with broad therapeutic coverage including cardiovascular and oncology. Comparable as a SZSE-listed Chinese pharma with manufacturing scale, but operates more broadly than the modern TCM niche.
• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical groups with both manufacturing and distribution. Comparable as a Shanghai-based, SZSE/HKEX-listed pharma with respiratory and cardiovascular exposure, but at significantly larger scale and broader portfolio.
• Yangshengtang / 养生堂 (related: CSPC Pharmaceutical): Diversified Chinese pharmaceutical and health products group with TCM, chemical drugs, and consumer health offerings. Comparable therapeutic-area breadth and combination of prescription + big health product strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shanghai-kaibao-pharmaceutical-co-ltd-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Kaibao Pharmaceutical